Barclays Maintains Overweight on Insmed, Lowers Price Target to $207
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.
Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.